Thank you for Subscribing to Life Science Review Weekly Brief
CellGenix announces the appointment of Daniel Spatz as Vice President of Sales, Marketing & Logistics and a member of the management team.
FREMONT, CA: CellGenix, a worldwide manufacturing leader in GMP-grade raw materials for cell therapy, gene therapy, and tissue-engineered items, is happy to announce the addition of Daniel Spatz as Vice President of Sales, Marketing & Logistics and a member of the management team.
Daniel became the Head of Marketing & Sales and Logistics at CellGenix in 2021. In their headquarters in Germany, he controls the overall global sales and marketing department, along with logistics and customer support. He will now serve these critical areas in the management team and help to improve their global position as a premium raw material supplier. Prof. Dr. Felicia M. Rosenthal (Chief Executive Officer), Dr. Bernd Leistler (Vice President Production), Dr. Udo Nirenberg (Vice President Quality Control), and Dr. Till Puschmann (Vice President R&D and Business Development) completes the management team.
“We are delighted to welcome Daniel Spatz in our management team,” said Prof. Felicia Rosenthal, CEO of CellGenix. “Daniel has extensive global marketing and sales experience in the life science field and a proven track record. I am confident that he will prove to be an important addition to our management team as CellGenix continues to expand and build on its leading position as premium supplier of high-quality raw materials for cell and gene therapy manufacturing. We welcome him in our management team and look forward to continuing working with him.”
“I am very excited to join the management team of CellGenix and help build on the solid foundation developed over the last 25+ years,” said Daniel Spatz. “With comprehensive knowledge and hands-on experience of developing a cell therapy ourselves, CellGenix is an expert in GMP manufacturing of raw materials for cell and gene therapies. I am looking forward to sharing my vast experience and know-how to continue to drive CellGenix growth in the cell and gene therapy market and ensure continuous and optimal customer support.”